Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis

OBJECTIVES: National Danish guidelines in May 2015 dictated a mandatory switch from originator infliximab (INX) to biosimilar CT-P13 in patients with inflammatory rheumatic disease. We investigated if this non-medical switch changed use of outpatient hospital resources. METHODS: Observational cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Glintborg, Bente, Sørensen, Jan, Hetland, Merete Lund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045751/
https://www.ncbi.nlm.nih.gov/pubmed/30018807
http://dx.doi.org/10.1136/rmdopen-2018-000710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045751/
https://www.ncbi.nlm.nih.gov/pubmed/30018807
http://dx.doi.org/10.1136/rmdopen-2018-000710

Ejemplares similares